Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26856936 | 0.90 | HPGD (0.47) | KDM4E | |
| SCHEMBL26856993 | 0.89 | HPGD (0.44) | MMP12PIK3CAPIK3CGKDM4E | |
| SCHEMBL26856997 | 0.89 | MAPK8 (0.44) | MMP12PIK3CAPIK3CGMETTL3MMP2 | |
| SCHEMBL26856958 | 0.87 | PIK3CA (0.42) | MMP12PIK3CAPIK3CGMETTL3MMP2 | |
| SCHEMBL26857005 | 0.86 | ACKR3 (0.42) | MMP12PIK3CAPIK3CGKDM4EMMP2 | |
| SCHEMBL26856933 | 0.86 | PIK3CA (0.46) | MMP12PIK3CAPIK3CGMMP2MMP8 | |
| SCHEMBL26856937 | 0.83 | PIK3CG (0.48) | MMP12PIK3CAPIK3CGKDM4EMETTL3 | |
| SCHEMBL26856930 | 0.82 | PIK3CG (0.47) | MMP12PIK3CAPIK3CGKDM4EMETTL3 | |
| SCHEMBL26856929 | 0.81 | MAPK8 (0.41) | MMP12PIK3CAPIK3CGPIK3CDPIK3CB | |
| SCHEMBL26857317 | 0.81 | MAPK10 (0.42) | MMP12PIK3CAPIK3CGTTKPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | MMP12 4866/4885PIK3CA 841/4885PIK3CG 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.